Triglycerides and risk of atherosclerotic cardiovascular disease: An update

Low-density lipoprotein cholesterol is a well-known causal factor for atherosclerotic cardiovascular disease, and is the primary target of lipid-lowering therapy. There is, however, still a substantial risk of atherosclerotic cardiovascular disease events despite intensive statin therapy, and data f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of cardiovascular diseases Jg. 114; H. 2; S. 132
Hauptverfasser: Farnier, Michel, Zeller, Marianne, Masson, David, Cottin, Yves
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands 01.02.2021
Schlagworte:
Animals
Atherosclerosis - blood
Atherosclerosis - diagnosis
Atherosclerosis - epidemiology
Atherosclerosis - prevention & control
Biomarkers - blood
Dyslipidemias - blood
Dyslipidemias - diagnosis
Dyslipidemias - epidemiology
Dyslipidemias - therapy
Heart Disease Risk Factors
Humans
Hypolipidemic Agents - therapeutic use
Prognosis
Risk Assessment
Risk Reduction Behavior
Triglycerides - blood
Remnants
Triglyceride-rich lipoproteins
Triglycérides
Cardiovascular risk
Risque cardiovasulaire
Triglycerides
Lipoprotéines riches en triglycérides
ISSN:1875-2128, 1875-2128
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Low-density lipoprotein cholesterol is a well-known causal factor for atherosclerotic cardiovascular disease, and is the primary target of lipid-lowering therapy. There is, however, still a substantial risk of atherosclerotic cardiovascular disease events despite intensive statin therapy, and data from clinical trials suggest that an elevated concentration of triglycerides is a marker of residual cardiovascular risk on low-density lipoprotein-lowering therapy. Serum triglycerides are a biomarker for triglyceride-rich lipoproteins, and several lines of evidence indicate that triglyceride-rich lipoproteins and their cholesterol-enriched remnant particles are associated with atherogenesis. Moreover, genetic data in humans strongly suggest that the remnants of triglyceride-rich lipoproteins are a causal cardiovascular risk factor. Although lifestyle changes remain the cornerstone of management of hypertriglyceridaemia, a recent trial with high doses of the omega-3 fatty acid icosapent ethyl showed a significant reduction in cardiovascular events that was not explained by the reduction in triglycerides alone. In patients with elevated triglycerides, several novel drugs are in development to reduce the residual risk on statin therapy linked to an excess of atherogenic triglyceride-rich lipoproteins. In this review, we provide an update on the biology, epidemiology and genetics of triglycerides, and the risk of atherosclerotic cardiovascular disease.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1875-2128
1875-2128
DOI:10.1016/j.acvd.2020.11.006